#15

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 09/316,199	ATTY. DOCKET NO.: C1040/7006
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: May 21, 1999	
	APPLICANT: McCluskie et al.	
Sheet 1 of 4	GROUP ART UNIT: 1633	**EXAMINER: D. Nguyen**

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document Number	U.S. Patent Document Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		5,780,448	B1	Davis	07/14/1998
		5,972,346	B1	Hauser et al.	10/26/1999

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document Office/ Country	Foreign Patent Document Number	Foreign Patent Document Kind Code	Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		WO	98/49348	A1	ISIS Pharmaceuticals, Inc.	11/05/1998	
		WO	99/58118	A2	CpG ImmunoPharmaceuticals GmbH	11/18/1999	

OTHER ART — **NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
		AGRAWAL, S. et al., "Pharmacokinetics of Antisense Oligonucleotides", *Clin. Pharmacokinét.*, 1995, Pages 7-16, Vol. 28, No. 1		
		AGRAWAL, S., "Antisense oligonucleotides: towards clinical trials", *TIBTECH*, October 1996, Pages 376-387, Vol. 14, Elsevier Science		
		AGRAWAL, S. et al., "Toxicologic Effects of an Oligodeoxynucleotide Phosphorothioate and Its Analogs Following Intravenous Administration in Rats", *Antisense & Nucleic Acid Drug Development*, 1997, Pages 575-584, Vol. 7, Mary Ann Liebert, Inc.		
		ALLISON, A.C. et al., "The Development of an Adjuvant Formulation that Elicits Cell-Mediated and Humoral Immune Responses to Virus Subunit and Other Antigens", *Immunopharmacology of Infectious Diseases: Vaccine Adjuvants and Modulators of Non-Specific Resistance*, 1987, Pages 191-201, Alan R. Liss, Inc.		
		ANDERSON, G.P. et al., "T_H2 and 'T_H2-like' cells in allergy and asthma: pharmacological perspectives", *TIPS*, 1994, Pages 324-332, Vol. 15		
		ANFOSSI, G. et al., "An oligomer complementary to *c-myb*-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines", *Proc. Natl. Acad. Sci. USA*, May 1989, Pages 3379-3383, Vol. 86		
		BALLAS, Z.K. et al., "A patient with simultaneous absence of "classical" natural killer cells ($CD3^-$, $CD16^+$. and $NKH1^+$) and expansion of $CD3^+$, $CD4^-$, $CD8^-$, $NKH1^+$ subset", *J. Allergy Clin. Immunol.*, February 1990, Pages 453-459, Vol. 85, No. 2		
		BERNHARD, M.I. et al., "Monocyte-Macrophage Mediated Antibody Dependent and Independent Cell Mediated Cytotoxicity in Normals and Cancer Patients", *Proc. of AACR and ASCO*, Page C-159, Vol. 22(372)		
		CATTANEO, R. et al., "Signals regulating hepatitis B surface antigen transcription", *Nature*, September 22, 1983, Pages 336-338, Vol. 305, Macmillan Journals Ltd.		
		CONSTANT, P. et al., "Stimulation of Human γδ T Cells by Nonpeptidic Mycobacterial Ligands", *Science*, April 8, 1994, Pages 267-270, Vol. 264		
		COSSUM, P.A. et al., "Pharmacokinetics of a ^{14}C-Labeled Phosphorothioate Oligonucleotide, ISIS 2105, after Intradermal Administration to Rats", *Journal of Pharmacology and Experimental Therapeutics*, 1994, Pages 89-94, Vol. 269, No. 1, USA		
		DAVIS, H.L. et al., "DNA vaccine for hepatitis B: Evidence for immunogenicity in chimpanzees and comparison with other vaccines", *Proc. Natl. Acad. Sci. USA*, July 1996, Pages 7213-7218, Vol. 93		
		DAVIS, H.L., "Plasmid DNA expression systems for the purpose of immunization", *Curr. Opin. Biotechnol.*, October 1997, Pages 635-646, Vol. 8, No. 5		

7/16/02

		DEMATOS, P. et al., "Pulsing of Dendritic Cells With Cell Lysates From Either B16 Melanoma or MCA-106 Fibrosarcoma Yields Equally Effective Vaccines Against B16 Tumors in Mice", *Journal of Surgical Oncology*, 1998, Pages 79-91, Vol. 68, Wiley-Liss, Inc.		
		DIGNAM, J.D. et al., "Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei", *Nucleic Acids Research*, November 5, 1983, Pages 1475-1489, Vol. 11, IRL Press Limited, Oxford, England		
		ENGLEMAN, E.G., "Dendritic cells: Potential role in cancer therapy", *Cytotechnology*, 1997, Pages 1-8, Vol. 25, Kluwer Academic Publishers, Netherlands		
		ETCHART, N. et al., "Class 1-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin", *Journal of General Virology*, 1997, Pages 1577-1580, Vol. 78, No. 7		
		FIELDS, R.C. et al., "Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses *in vitro* and *in vivo*", *Proc. Natl. Acad. Sci. USA*, August 1998, Pages 9482-9487, Vol. 95, The National Academy of Sciences		
		FUJIEDA, S. et al., "Effect of OK-432 on Cytotoxic Activity in Cancer Patients without Tumor Burden", *Anticancer Research*, 1992, Pages 1941-1946, Vol. 12		
		FULLER, D.H. et al., "Induction of immunodeficiency virus-specific immune responses in rhesus monkeys following gene gun-mediated DNA vaccination", *J. Med. Primatol.*, 1996, Pages 236-241, Vol. 25, USA		
		FYNAN, E.F. et al., "DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations", *Proc. Natl. Acad. Sci. USA*, December 1993, Pages 11478-11482, Vol. 90		
		GARRIGAN, K. et al., "Functional Comparison of Spleen Dendritic Cells and Dendritic Cells Cultured *In Vitro* From Bone Marrow Precursors", *Blood*, November 1, 1996, Pages 3508-3512, Vol. 88, No. 9		
		GATELY, M.K., "Interleukin-12: A Recently Discovered Cytokine with Potential for Enhancing Cell-Mediated Immune Responses to Tumors", *Cancer Investigation*, 1993, Pages 500-506, Vol. 11, No. 4, Marcel Dekker, Inc.		
		GLUCKMAN, J.C. et al., "*In vitro* generation of human dendritic cells and cell therapy", *Cytokines, Cellular and Molecular Therapy*, 1997, Pages 187-196, Vol. 3, Martin Dunitz Ltd.		
		GRAMZINSKI, R.A. et al., "Immune Response to a Hepatitis B DNA Vaccine in *Aotus* Monkeys: A Comparison of Vaccine Formulation, Route, and Method of Administration", *Molecular Medicine*, February 1998, Pages 109-118, Vol. 4, No. 2		
		GROUARD, G. et al., "The Enigmatic Plasmacytoid T Cells Develop into Dendritic Cells with Interleukin (IL)-3 and CD40-Ligand", *J. Exp. Med.*, March 17, 1997, Pages 1101-1111, Vol. 185, No. 6, The Rockefeller University Press		
		GUERY, J.C. et al., "Dendritic Cells are the Most Efficient in Presenting Endogenous Naturally Processed Self-Epitopes to Class II-Restricted T Cells", *The Journal of Immunology*, 1995, Pages 536-544, Vol. 152, No. 2		
		HAMBLIN, T.J., "*Ex vivo* Activation and Retransfusion of White Blood Cells", *Curr. Stud. Hematol. Blood Transf.*, 1990, Pages 249-266, Vol. 57		
		HARTMANN, G. et al., "CpG *DNA:* A potent signal for growth, activation, and maturation of human dendritic cells", *Proc. Natl. Acad. Sci. USA*, August 1999, Pages 9305-9310, Vol. 96		
		HSU, F.J. et al., "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells", *Nature Medicine*, January 1996, Pages 52-58, Vol. 2, No. 1		
		JAKOB, T. et al., "Activation of Cutaneous Dendritic Cells by CpG-Containing Oligodeoxynucleotides: A Role for Dendritic Cells in the Augmentation of Th1 Responses by Immunostimualtory DNA", *The Journal of Immunology*, 1998, Pages 3042-3049, Vol. 161, No. 6		
		JAKOB, T. et al., "Bacterial DNA and CpG-Containing Oligodeoxynucleotides Activate Curaneous Dendritic Cells and Induce IL-12 Production: Implications for the Augmentation of Th1 Responses", *Int. Arch. Allergy Immunol.*, 1999, Pages 457-461, Vol. 118		
		KATAOKA, T. et al., "Immunotherapeutic Potential in Guinea-Pig Tumor Model of Deoxyribonucleic Acid from *Mycobacterium Bovis* BCG Complexed with Poly-L-Lysine and Carboxy-Methylcellulose", *Jpn. J. Med. Sci. Biol.*, 1990, Pages 171-182, Vol. 43		
		KOU, K. et al., "Analysis and regulation of interferon-gamma production by peripheral blood lymphocytes from patients with bronchial asthma", *Arerugi*, March 1994, Abstract, Pages 482-491, Vol. 43, No. 3		
		KOLITZ, J.E. et al., "The Immunotherapy of Human Cancer with Interleukin 2: Present Status and Future Directions", *Cancer Investigation*, 1991, Pages 529-542, Vol. 9, No. 5, Marcel Dekker, Inc.		
		KURAMOTO, E. et al., "*In Situ* Infiltration of Natural Killer-Like Cells Induced by Intradermal Injection of the Nucleic Acid Fraction from BCG", *Microbiol. Immunol.*, 1989, Pages 929-940, Vol. 33, No. 11		
		KURAMOTO, E. et al., "Changes of Host Cell Infiltration into Meth A Fibrosarcoma Tumor During the Course of Regression Induced by Injections of a BCG Nucleic Acid Fraction", *Int. J. Immunopharmac.*, 1992, Pages 773-782, Vol. 14, No. 5, Pergamon Press Ltd.		

7/16/03

		LACOUR, J., "Clinical Trials Using Polyadenylic-Polyuridylic Acid as an Adjuvant to Surgery in Treating Different Human Tumors", *Journal of Biological Response Modifiers*, 1985, Pages 538-543, Vol. 4, Raven Press, New York		
		LANZAVECCHIA, A., "License to Kill", *Nature*, June 4, 1998, Pages 413-414, Vol. 393		
		LI, Z. et al., "Desmin sequence elements regulating skeletal muscle-specific expression in transgenic mice", *Development*, 1993, Pages 947-959, Vol. 117, The Company of Biologists Limited, Great Britain		
		LIANG, H. et al., "Activation of Human B Cells by Phosphorothioate Oligodeoxynucleotides", *J. Clin. Invest.*, September 1996, Pages 1119-1129, Vol. 98, No. 5		
		LIPFORD, G.B. et al., "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines", *Eur. J. Immunol.*, 1997, Pages 3420-3426, Vol. 27, Wiley-VCH Verleg GmbH		
		LUDEWIG, B. et al., "Dendritic Cells Efficiently Induce Protective Antiviral Immunity", *Journal of Virology*, May 1998, Pages 3812-3818, Vol. 72, No. 5		
		MORAHAN, P.S. et al., "Comparative Analysis of Modulators of Nonspecific Resistance Against Microbial Infections", *Immunopharmacology of Infection Diseases: Vaccine Adjuvants and Modulators of Non-Specific Resistance*, 1987, Pages 313-324, Alan R. Liss, Inc.		
		NAIR, S.K. et al., "Regression of Tumors in Mice Vaccinated with Professional Antigen-Presenting Cells Pulsed with Tumor Extracts", *Int. J. Cancer*, 1997, Pages 706-715, Vol. 70, Wiley-Liss, Inc.		
		NESTLE, F.O. et al., "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells", *Nature Medicine*, March 1998, Pages 328-332, Vol. 4, No. 3		
		O'DOHERTY, U. et al., "Dendritic Cells Freshly Isolated from Human Blood Express CD4 and Mature into Typical Immunostimulatory Dendritic Cells after Culture in Monocyte-conditioned Medium", *J. Exp. Med.*, September 1993, Pages 1067-1078, Vol. 178, The Rockefeller University Press		
		OKADA, H. et al., "Bone Marrow-Derived Dendritic Cells Pulsed with a Tumor-Specific Peptide Elicit Effective Anti-Tumor Immunity Against Intracranial Neoplasms", *Int. J. Cancer*, 1998, Pages 196-201, Vol. 78, Wiley-Liss, Inc.		
		PETERSON, M.G. et al., "Transcription Factors: A New Frontier in Pharmaceutical Development?", *Biochemical Pharmacology*, 1994, Pages 127-128, Vol. 47, No. 1, Elsevier Science Ltd., Great Britain		
		POTTRATZ, S.T. et al., "17β-Estrodiol Inhibits Expression of Human Interleukin-6 Promoter-Reporter Constructs by A Receptor-dependent Mechanism", *The Journal of Clinical Investigation, Inc.*, March 1994, Pages 944-950, Vol. 93		
		PRINCE, A.M. et al., "Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus", *Vaccine*, 1997, Pages 916-919, Vol. 15, No. 8		
		REISFELD, R.A., "Monoclonal Antibodies in Cancer Immunotherapy", *Clinics in Laboratory Medicine*, June 1992, Pages 201-216, Vol. 12, No. 2		
		RIDGE, J.P. et al., "A conditioned dendritic cell can be a temporal bridge between a $CD4^+$ T-helper and a T-killer cell", *Nature*, June 4, 1988, Pages 474-478, Vol. 393		
		ROBINSON, S.P. et al., "Developmental Aspects of Dendritic Cells *In Vitro* and *In Vivo*", *Leukemia and Lymphoma*, 1997, Pages 477-490, Vol. 29, Overseas Publishers Association Amsterdam B.V.		
		ROBINSON, H.L., "Nucleic acid vaccines: an overview", *Vaccine*, 1997, Pages 785-787, Vol. 15, No. 8, Elsevier Science Ltd., Great Britain		
		ROJANASAKUL, Y., "Antisense oligonucleotide therapeutics: drug delivery and targeting", *Advanced Drug Delivery Reviews*, 1996, Pages 115-131, Vol. 18, Elsevier Science B.V.		
		ROMANI, N. et al., "Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability", *Journal of Immunological Methods*, 1996, Pages 137-151, Vol. 196, Elsevier Science B.V.		
		ROSENBERG, S.A., "Immunotherapy of Cancer by Systemic Administration of Lymphoid Cells Plus Interleukin-2", *Journal of Biological Response Modifiers*, 1984, Pages 501-511, Vol. 3, Raven Press, New York		
		ROSENBERG, S.A. et al., "Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer", *N.E. J. of Med.*, 1985, Pages 1485-1492, Vol. 113, No. 23		
		ROSENBERG, S.A. et al., "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma", *Nature Medicine*, March 1998, Pages 321-327, Vol. 4, No. 3		
		SANDS, H. et al., "Biodistribution and Metabolism of Internally ^{3}H-Labeled Oligonucleotides. I. Comparison of a Phosphodiester and a Phosphorothioate", *Molecular Pharmacology*, 1994, Pages 932-943, Vol. 45		
		SARMIENTO, U.M. et al., "*In Vivo* Toxicological Effect of *rel* A Antisense Phosphorothioates in CD-1 Mice", *Antisense Research and Development*, 1994, Pages 99-107, Vol. 4, Mary Ann Liebert, Inc.		

7/16/03

		SCHOENBERGER, S.P. et al., "T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions", *Nature*, June 4, 1988, Pages 480-483, Vol. 393		
		SEDEGAH, M. et al., "Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein", *Proc. Natl. Acad. Sci. USA*, October 1994, Pages 9866-9870, Vol. 91		
		SHIMADA, S. et al., "Antitumor Activity of the DNA Fraction from *Mycobacterium bovis* BCG. II. Effects on Various Syngeneic Mouse Tumors", *JNCI*, March 1985, Pages 681-688, Vol. 74, No. 3		
		SHIMADA, S. et al., "*In vivo* Augmentation of Natural Killer Cell Activity with a Deoxyribonucleic Acid Fraction of BCG", *Jpn. J. Cancer Res.*, August 1986, Pages 808-816, Vol. 77		
		SPARWASSER, T. et al., "Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells", *Eur. J. Immunol.*, 1998, Pages 2045-2054, Vol. 28, Wiley-VCH Verlag GmbH		
		STEIN, C.A. et al., "Antisense Oligonucleotides as Therapeutic Agents – Is the Bullet Really Magical?", *Science*, August 20, 1993, Pages 1004-1012, Vol. 261		
		STEINMAN, R.M., "Dendritic cells and immune-based therapies", *Experimental Hematology*, 1996, Pages 859-862, Vol. 24		
		STEVENSON, H.C. et al., "The Treatment of Cancer with Activated Cytotoxic Leukocyte Subsets", *Artif. Organs*, 1988, Pages 128-136, Vol. 12, No. 2		
		THREADGILL, D.S. et al., "Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide", *Vaccine*, 1998, Pages 76-82, Vol. 16, No. 1, Elsevier Science Ltd., Great Britain		
		TJOA, B.A. et al., "Evaluation of Phase I/II Clinical Trails in Prostate Cancer With Dendritic Cells and PSMA Peptides", *The Prostate*, 1998, Pages 39-44, Vol. 36, Wiley-Liss, Inc.		
		TOPALIAN, S.L. et al., "Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials", *Journal of Immunological Methods*, 1987, Pages 127-141, Vol. 102		
		TORPEY III, D. et al., "Effects of Adoptive Immunotherapy with Autologous $CD8^+$ T Lymphocytes on Immunologic Parameters: Lymphocyte Subsets and Cytotoxic Activity", *Clinical Immunology and Immunopathology*, September 1993, Pages 263-272, Vol. 68, No. 3, Academic Press, Inc.		
		VALENZUELA, P. et al., "Synthesis and assembly of hepatitis B virus surface antigen particles in yeast", *Nature*, July 22, 1982, Pages 347-350, Vol. 298, Macmillan Journals Ltd.		
		VAN SCHOOTEN, W.C.A. et al., "Biological properties of dendritic cells: implications to their use in the treatment of cancer", *Molecular Medicine Today*, June 1997, Pages 254-260, Elsevier Science Ltd.		
		VOGELS, M.T.E. et al., "Use of Immune Modulators in Nonspecific Therapy of Bacterial Infections", *Antimicrobial Agents and Chemotherapy*, January 1992, Pages 1-5, Vol. 36, No. 1		
		WAAG, D.M. et al., "Injection of Inactivated Phase I *Coxiella burnetti* Increases Non-specific Resistance to Infection and Stimulates Lymphokine Production in Mice", *Annals New York Academy of Sciences*, 1990, Pages 203-214, Vol. 590		
		WALKER, C. et al., "Activated T Cells and Cytokines in Bronchoalveolar Lavages from Patients with Various Lung Diseases Associated with Eosinophilia", *Am. J. Respir. Crit. Care Med.*, 1994, Pages 1038-1048, Vol. 150		
		WALKER, P.S. et al., "Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-γ-dependent mechanisms", *Proc. Natl. Acad. Sci. USA*, June 1999, Pages 6970-6975, Vol. 96		
		WANG, B. et al, "Gene inoculation generates immune responses against human immunodeficiency virus type I", *Proc. Natl. Acad. Sci. USA*, May 1993, Pages 4156-4160, Vol. 90		
		WEINER, G.J. et al., "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization", *Proc. Natl. Acad. Sci. USA*, September 1997, Pages 10833-10837, Vol. 94		
		XIANG, Z.Q. et al., "The effect of interferon-γ on genetic immunization", *Vaccine*, 1997, Pages 896-898, Vol. 15, No. 8, Elsevier Science Ltd., Great Britain		
		YANG, S. et al., "Immunotherapeutic Potential of Tumor Antigen-Pulsed and Unpulsed Dendritic Cells Generated from Murine Bone Marrow", *Cellular Immunology*, 1997, Pages 84-95, Vol. 179, Academic Press		
		ZELPHATI, O. et al., "Inhibition of HIV-1 Replication in Cultured Cells with Antisense Oligonucleotides Encapsulated in Immunoliposomes", *Antisense Research and Development*, 1993, Pages 323-338, Vol. 3, Mary Ann Liebert, Inc.		

EXAMINER	DATE CONSIDERED
	7/16/03

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

#4 #16

FORM PTO-1449(Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.: C1040/7006	SERIAL NO.: 09/31[illegible]/99
	APPLICANT: Davis, et al.	
	FILING DATE: May 21, 1999	GROUP: 1633

U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate

FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes	Translation No
Q	B18	WO 99/43350	09/02/99	PCT				
	B19	WO 99/33488	07/08/99	PCT				
	B20	WO 98/55495	12/10/98	PCT				
	B21	WO 98/32462	07/30/98	PCT				
V	B22	WO 98/16247	04/23/98	PCT				

OTHER ART
(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

Q		/	Davis, et al., "CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans", *Vaccine* 18:1920-1924 (2000)
|		/	Davis, H.L., "Plasmid DNA expression systems for the purpose of immunization", *Current Biology*, 16:42:36 (1997)
		/	Doe, et al., "Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmic DNA is facilitated by bone marrow-derived cells", *Proc. Natl. Acad. Sci.* USA, 93:8578-8583 (1996)
		/	Jones, et al., "Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys", *Vaccine*, 3065-3071 (1999)
		/	Kataoka, et al., "Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG", Jpn. J. Cancer Res., 83:244-247 (1992)
|		/	Klinman, et al., "Immune recognition of foreign DNA: a cure for bioterrorism", *Immunity*, 11:123-129 (1999)
V		/	Threadgill, et al., "Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide", *Vaccine* 16(1):76-82 (1998)

EXAMINER	DATE CONSIDERED 7/14/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant

Supp IDS #21

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 09/316,199	ATTY. DOCKET NO.: C01040.70006.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: May 21, 1999	CONFIRMATION NO.: 7506
	APPLICANT: McCluskie et al.	
Sheet | | of	GROUP ART UNIT: 1632	EXAMINER: Dave T. Nguyen

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document Number	U.S. Patent Document Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document Office/ Country	Foreign Patent Document Number	Foreign Patent Document Kind Code	Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C1	McCluskie et al., "Cutting Edge: CpG DNA is a Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice", *J. Immunol.*, 161:4463,4466, 1998		

EXAMINER	DATE CONSIDERED
	7/16/03

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]